Celgene Corp. buy matumba
Start price
22.10.11
/
50%
€24.05
Target price
28.12.11
€26.08
Performance (%)
8.41%
End price
28.12.11
€26.08
Summary
This prediction ended on 28.12.11 with a price of €26.08. With a performance of 8.41%, the BUY prediction by matumba for Celgene Corp. closed with a slight gain. matumba has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Celgene Corp. | - | - | - | - |
| iShares Core DAX® | -3.173% | 1.229% | 2.539% | 51.993% |
| iShares Nasdaq 100 | -1.006% | 0.381% | 32.247% | 87.194% |
| iShares Nikkei 225® | -3.600% | 1.005% | 59.535% | 72.473% |
| iShares S&P 500 | 0.214% | 2.924% | 24.524% | 69.844% |
Comments by matumba for this prediction
In the thread Celgene Corp. diskutieren
risikobereit?
Revlimid Präparat gegen Krebs soll 2012 ein Umsatzplus von 30% bringen (3,15MRD Dollar)
Europ. Arzneimittelagentur hat sich positiv geäußert- dies ermögl. gute Chancen